Shares of Poolbeg Pharma PLC (LON:POLB – Get Free Report) hit a new 52-week low on Monday . The stock traded as low as GBX 2.70 ($0.03) and last traded at GBX 2.73 ($0.04), with a volume of 636335 shares changing hands. The stock had previously closed at GBX 2.71 ($0.04).
Analysts Set New Price Targets
Separately, Shore Capital restated a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, January 2nd.
Poolbeg Pharma Stock Up 0.7 %
Poolbeg Pharma Company Profile
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Further Reading
- Five stocks we like better than Poolbeg Pharma
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Growth Stocks: What They Are, Examples and How to Invest
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Options Trading – Understanding Strike Price
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
